Compounded Tirzepatide: What to Know
Compounded tirzepatide post-shortage: what's still legal, what's risky, how to vet a pharmacy, and the dosing math vs brand pens.
Updated May 6, 2026 · 5 min read
Compounded tirzepatide is a different animal than compounded semaglutide in 2026. The FDA declared the tirzepatide shortage resolved in late 2024, finalizing the determination in early 2025. That decision dramatically narrowed the legal pathway for compounded tirzepatide, even as compounded semaglutide remains in a more ambiguous middle state.
If you're considering compounded tirz, the rules, supply chain, and safety story have all shifted recently. Here's what's accurate as of 2026.
What "compounded" actually means
A compounded medication is one prepared by a licensed pharmacist for a specific patient (or batch), rather than manufactured by the original drug company. Compounding is legal under specific federal regulations — most relevantly:
- 503A pharmacies — traditional compounding pharmacies, prepare patient-specific prescriptions.
- 503B outsourcing facilities — register with the FDA, can produce compounded drugs in bulk for clinics, must follow stricter standards (including cGMP).
During the FDA-declared tirzepatide shortage (December 2022 to October 2024), both 503A and 503B pharmacies could legally compound tirzepatide as a workaround. With the shortage resolved, the legal grounds narrowed sharply.
What changed in 2024–2025
| During shortage (2022–2024) | After shortage resolved (2025+) | |
|---|---|---|
| 503B bulk compounding | Permitted | Generally prohibited |
| 503A patient-specific compounding | Permitted broadly | Permitted only for clinically necessary personalization |
| Telehealth "compounded GLP-1" subscriptions | Booming market | Most providers stopped tirzepatide; many pivoted to semaglutide |
| Enforcement | Light | FDA and state boards more active |
The "clinically necessary personalization" carve-out is the live battleground. Some compounders argue that pairing tirzepatide with B12, glycine, or another active ingredient creates a meaningfully different formulation. The FDA has signaled skepticism. Court cases are ongoing.
The practical effect: legitimate compounded tirzepatide is harder to find than it was in 2024, and what's available is more likely to be either a personalized formulation or operating in a legal gray zone. Compounded semaglutide remains more accessible — see our compounded safety coverage.
How compounded tirzepatide compares to brand
Pharmacologically, compounded tirzepatide is the same molecule as Mounjaro and Zepbound when prepared correctly. There are no FDA-approved generics. What differs is:
| Brand (Mounjaro/Zepbound) | Compounded tirzepatide | |
|---|---|---|
| Manufacturer oversight | FDA-inspected Lilly facilities | 503A pharmacy or 503B outsourcer |
| Sterility testing | Standardized | Varies by pharmacy |
| Active ingredient source | Lilly | Various API suppliers |
| Salt forms | Tirzepatide (no salt forms in current use) | Generally the same; salt-form issues less common than with sema |
| Format | Pre-filled pens / single-dose vials | Multi-dose vials reconstituted with bacteriostatic water |
| Concentration | Fixed per pen | Variable per pharmacy |
| Cost | $1,000–1,400/mo brand; LillyDirect cheaper | $200–500/mo typical when available |
The salt-form question that haunted compounded semaglutide (semaglutide sodium vs the parent semaglutide) hasn't been a major issue with tirzepatide. Most compounded tirz is prepared as the parent peptide. Still worth confirming with any compounder you use.
How to vet a compounding pharmacy
If you're going to use compounded tirzepatide, due diligence is non-negotiable. The questions to ask:
- Are you 503A or 503B? 503B is a higher regulatory standard for bulk preparation. 503A is fine for true patient-specific compounding.
- Where do you source your API? Reputable answer: a US-based supplier with a verifiable Drug Master File. Non-answer: vague references to "GMP suppliers."
- What testing do you run on each batch? Minimum: identity, potency, sterility, endotoxin. Ask for a Certificate of Analysis (CoA) for the specific lot.
- What's your beyond-use date (BUD)? Reconstituted tirzepatide stored properly is generally stable for several weeks; any pharmacy claiming 6+ months should raise eyebrows.
- Are you licensed in my state? Verify with your state board of pharmacy. This matters legally.
- What's your prescribing relationship? Compounded medications still require a valid prescription from a clinician licensed in your state. "No prescription needed" is illegal and a red flag.
If a telehealth provider can't or won't answer these, walk away. The FDA has issued multiple warning letters to compounders that mishandled tirzepatide; counterfeit and underdosed product has been documented.
Dosing identical, math is on you
Compounded tirzepatide milligram doses match the brand schedule exactly:
| Step | Brand pen | Compounded equivalent (10 mg/mL vial, units on insulin syringe) |
|---|---|---|
| 2.5 mg | 2.5 mg pen | 25 units |
| 5 mg | 5 mg pen | 50 units |
| 7.5 mg | 7.5 mg pen | 75 units |
| 10 mg | 10 mg pen | 100 units |
| 12.5 mg | 12.5 mg pen | 125 units (1.25 mL) |
| 15 mg | 15 mg pen | 150 units (1.5 mL) |
That table assumes a 10 mg/mL vial. Concentrations vary — your compounder will tell you. Always verify your concentration before drawing. A wrong-concentration assumption is the most common dosing error in the compounded space. Run the math through our calculator.
For the underlying schedule, see tirzepatide dosing schedule.
Storage and handling
- Refrigerate between 36–46°F (2–8°C). Do not freeze.
- After reconstitution, most compounders specify a BUD of 28–56 days refrigerated.
- Bring to room temperature for 15–30 minutes before injecting to reduce site discomfort.
- Use a new sterile insulin syringe and needle for every dose. Never share syringes.
- Rotate injection sites — abdomen, thigh, upper arm.
Red flags
Stop using and contact your prescriber if you notice:
- Cloudy, discolored, or particulate-containing solution. Tirzepatide should be clear.
- Significant injection-site reactions (large welts, persistent pain, signs of infection).
- Unexpected loss of effect — this can suggest a low-potency batch.
- Symptoms that don't match your expected dose response at all.
When in doubt, switch to brand. Continuity of supply with a known product is worth a meaningful cost premium for many people.